3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Sarcoma
1
Lymphoid
1
Gastrointestinal
1
CNS
1
Conditions
Stomach Neoplasms
1
Sarcoma
1
Neuroblastoma
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Interventions
Doxorubicin
7
Radiotherapy
4
Radiation
3
Magnetic Resonance Spectroscopy
3
Ifosfamide
3
regorafenib
2
Temozolomide
2
Surgical Procedures, Operative
2
Methotrexate
2
Imatinib Mesylate
2
Etoposide
2
Drug Therapy
2
Cyclophosphamide
2
Cisplatin
2
veliparib
1
selinexor
1
pirarubicin
1
pazopanib
1
niraparib
1
merphos
1
liposomal doxorubicin
1
fludarabine phosphate
1
dostarlimab
1
capmatinib
1
cabozantinib
1
brigimadlin
1
apatinib
1
anlotinib
1
Zoledronic Acid
1
X-Rays
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
capmatinib
×
Sarcoma
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled